SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934	
(Amendment No. 5)*	
PharmaCyte Biotech, Inc.	
(Name of Issuer)	
Common Stock, \$0.0001 par value per share	
(Title of Class of Securities)	
717512X203	
(CUSIP Number)	
12/31/2024	
(Date of Event Which Requires Filing of this Statement)	
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:	
Rule 13d-1(b)	
Rule 13d-1(d)	
SCHEDULE 13G	
CUSIP No. 717512X203	
Names of Reporting Persons	
1 Mitchell P. Kopin	
Check the appropriate box if a member of a Group (see instructions)	
2 (a) (b)	
3 Sec Use Only	
Citizenship or Place of Organization	

UNITED STATES

Number of Shares Benefici ally Owned by Each Reporti ng Person	5	Sole Voting Power	
		0.00	
	6	Shared Voting Power	
		714,844.00	
	7	Sole Dispositive Power	
		0.00	
With:	8	Shared Dispositive Power	
	8	714,844.00	
	Aggregate Amount Beneficially Owned by Each Reporting Person		
9	714,844.00		
10	Check bo	x if the aggregate amount in row (9) excludes certain shares (See Instructions)	
11	Percent of class represented by amount in row (9)		
	9.99 %		
12	Type of Reporting Person (See Instructions)		
	HC, IN		

SCHEDULE 13G

|--|

1		Reporting Persons	
	Daniel B. Asher		
2	Check the appropriate box if a member of a Group (see instructions)		
	□ (a) □ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization		
	UNITED STATES		
		Sole Voting Power	
	5	82,727.00	
Number of			
Shares Benefici	6	Shared Voting Power	
ally Owned by Each Reporti ng Person With:		622,936.00	
	7	Sole Dispositive Power	
		82,727.00	
		Shared Dispositive Power	
	8	622,936.00	
0	Aggregate Amount Beneficially Owned by Each Reporting Person		
9	705,663.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)		

11	Percent of class represented by amount in row (9)
	9.99 %
12	Type of Reporting Person (See Instructions)
	HC, IN

SCHEDULE 13G

CUSIP No.	717512X203		
-----------	------------	--	--

1	Names of Reporting Persons		
	Intracoastal Capital LLC		
	Check the appropriate box if a member of a Group (see instructions)		
2	□ (a)□ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization		
4	DELAWARE		
		Sole Voting Power	
Number	5	0.00	
of Shares		Shared Voting Power	
Benefici ally Owned	6	714,844.00	
by Each Reporti	7	Sole Dispositive Power	
ng Person	'	0.00	
With:	8	Shared Dispositive Power	
	0	714,844.00	
	Aggregat	e Amount Beneficially Owned by Each Reporting Person	
9	714,844.00		
40	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)		
10			
44	Percent of class represented by amount in row (9)		
11	9.99 %		
12	Type of Reporting Person (See Instructions)		
12	00		

SCHEDULE 13G

Item 1.

(a) Name of issuer:

PharmaCyte Biotech, Inc.

(b) Address of issuer's principal executive offices:

3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169

(a)	Name of person filing:
	This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence:
	The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604
(c)	Citizenship:
	Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities:
	Common Stock, \$0.0001 par value per share
(e)	CUSIP No.:
	717512X203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	■ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	■ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	■ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	■ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filling as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

(k)

(a) Amount beneficially owned:

As of the close of business on December 31, 2024, each of Intracoastal and Mr. Kopin may have been deemed to have beneficial ownership of 714,844 shares of Common Stock, which consisted of (i) 527,376 shares of Common Stock held by Intracoastal and (ii) 187,468 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1"), and all such shares of Common Stock represented beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 6,968,134 shares of Common Stock outstanding as of December 9, 2024, as reported by the Issuer, plus (2) 187,468 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 312,532 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 129,147 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (III) 2,312,500 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acti

As of the close of business on December 31, 2024, Mr. Asher may have been deemed to have beneficial ownership of 705,663 shares of Common Stock, which consisted of (i) 527,376 shares of Common Stock held by Intracoastal, (ii) 82,727 shares of Common Stock held by Mr. Asher and (iii) 95,560 shares of Common Stock issuable upon exercise Intracoastal Warrant 1, and all such shares of Common Stock represented beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 6,968,134 shares of Common Stock outstanding as of December 9, 2024, as reported by the Issuer, plus (2) 95,560 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 404,440 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 608,553 shares of Common Stock issuable upon exercise of a warrant held by Mr. Asher (the "Asher Warrant") because the Asher Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Asher Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (III) 129,147 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliate

(b) Percent of class:

9.99 %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0 shares of Common Stock with respect to Mr. Kopin and Intracoastal. 82,727 shares of Common Stock with respect to Mr. Asher.

(ii) Shared power to vote or to direct the vote:

714,844 shares of Common Stock with respect to Mr. Kopin and Intracoastal. 705,663 shares of Common Stock with respect to Mr. Asher.

(iii) Sole power to dispose or to direct the disposition of:

0 shares of Common Stock with respect to Mr. Kopin and Intracoastal. 82,727 shares of Common Stock with respect to Mr. Asher.

(iv) Shared power to dispose or to direct the disposition of:

714,844 shares of Common Stock with respect to Mr. Kopin and Intracoastal. 705,663 shares of Common Stock with respect to Mr. Asher.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature: /s/ Mitchell P. Kopin
Name/Title: Mitchell P. Kopin
Date: 01/15/2025

Daniel B. Asher

Signature: /s/ Daniel B. Asher
Name/Title: Daniel B. Asher
Date: 01/15/2025

Intracoastal Capital LLC

Signature: /s/ Mitchell P. Kopin
Name/Title: Mitchell P. Kopin, Manager

Date: 01/15/2025